Table 2.
Complete, limited-duration, and specific cancer site prevalence per 1,000 males and females, 1992 and 2011
| Per 1,000 (proportion**) | |||||
|---|---|---|---|---|---|
| 1992 | 2011 | Relative change | |||
| Males | Complete prevalence* | 17.4 | 37.6 | 2.2 | |
| Duration | >10 years* | 4.8 (28%) | 11.6 (31%) | 2.4 | |
| 5–10 years | 3.8 (22%) | 9.6 (26%) | 2.5 | ||
| 1–5 years | 6.0 (35%) | 12.2 (32%) | 2.0 | ||
| Up to 1 year | 2.7 (16%) | 4.2 (11%) | 1.5 | ||
| Cancer site* Prostate | 3.0 (17%) | 13.5 (36%) | 4.5 | ||
| Melanoma | 3.7 (21%) | 7.0 (19%) | 1.9 | ||
| Colorectal | 2.6 (15%) | 4.5 (12%) | 1.7 | ||
| Females | Complete prevalence* | 22.71 | 36.5 | 1.6 | |
| Duration | > 10 years* | 8.3 (36%) | 14.7 (40%) | 1.8 | |
| 5–10 years | 5.0 (22%) | 9.0 (25%) | 1.8 | ||
| 1–5 years | 6.9 (30%) | 9.5 (26%) | 1.4 | ||
| Up to 1 year | 2.5 (11%) | 3.3 (9%) | 1.3 | ||
| Cancer site* | Breast | 7.6 (34%) | 14.4 (39%) | 2.7 | |
| Melanoma | 4.1 (18%) | 6.0 (16%) | 2.1 | ||
| Colorectal | 2.6 (12%) | 3.8 (10%) | 2.1 | ||
*Complete prevalence rates and rates of prevalence in those at 10 years or more postdiagnosis are corrected prevalence estimates. Cancer site data are for complete prevalence.
**Relates to the proportion of complete cancer prevalence accounted for by each subset of cancer prevalence (limited duration or cancer site).